Di’ao Group Chengdu Pharmaceutical

Di’ao Group is a prominent Chinese pharmaceutical enterprise headquartered in Chengdu, specializing in the development and production of cardiovascular and cerebrovascular medications. Established in 1988 as a high-tech spin-off from the Chinese Academy of Sciences, the company rose to prominence with its flagship product, Di’ao Xinxuekang, a natural medicine derived from steroidal saponins. Di’ao Group maintains a diverse portfolio that includes traditional Chinese medicines, chemical drugs, and biotechnological products. Notably, the company achieved a milestone in 2012 when its lead product became the first Chinese herbal medicine to receive marketing authorization in the European Union. Today, it operates extensive manufacturing facilities and research centers focused on modernizing natural medicine.